Nemaura ProBeat glucose monitor
The proBEAT sensor. [Image from Nemaura Medical]

Nemaura Medical (Nasdaq:NMRD) announced today that it now includes insulin under its DuoPack commercial license agreement.

Loughborough, UK-based Nemaura Medical entered into a commercial agreement in September 2021 with MySugarWatch DuoPack Limited (MSWDL). Under the agreement, Nemaura’s non-invasive, wearable skin patch sensors paired with prescription-only medicines for type 2 diabetes. This created the MySugarWatch-branded “DuoPack.”

Nemaura Medical develops and commercializes non-invasive, wearable diagnostic devices. Its sugarBEAT and proBEAT devices provide continuous glucose monitoring (CGM) plus additional capabilities.

Get the full story at our sister site, Drug Delivery Business News.